ArticleHLA2025
LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.
Article in HLA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Epstein-Barr virus-positive nodal T/NK-cell lymphoma presenting with hemophagocytic lymphohistiocytosis: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.HLA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epstein-Barr virus (EBV) infects up to 95% of the world's population and persists in B cells and epithelial cells. Uncontrolled proliferation of EBV-infected cells can result in the development of EBV-associated malignancies, for example, post-transplant lymphoproliferative disorder (PTLD) or nasopharyngeal cancer (NPC). It is estimated that 1.8% of deaths due to cancer worldwide are associated with EBV, and the treatment options are limited. As a new therapeutic approach, we developed chimeric antigen receptor T cells targeting EBV-derived latent membrane protein 2A (LMP2A_CAR-Ts). To enable specific elimination of malignant B cells infected with the intracellular pathogen, we utilised T-cell receptor (TCR)-like specificity to generate a CAR against the LMP2A-derived peptide CLGGLLTMV (CLG) presented in the context of HLA-A*02:01. To increase functionality in the tumour microenvironment, LMP2A_CAR-Ts were additionally equipped with inducible release of IL-12 (LMP2A_iIL-12_TRUCKs) or IL-18 (LMP2A_iIL-18_TRUCKs). LMP2A_CAR-Ts and LMP2A_iIL-18_TRUCKs specifically recognised HLA-A*02:01
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.